MedPath

4D Molecular Therapeutics Shifts Focus to Late-Stage Gene Therapy for Eye Disease

4D Molecular Therapeutics has decided to discontinue two clinical programs and cease funding for three other assets to concentrate resources on advancing late-stage studies for its gene therapy targeting eye disease, 4D-150.

In a strategic move to prioritize its most promising clinical candidate, 4D Molecular Therapeutics has announced the discontinuation of two clinical programs and the cessation of funding for three additional assets. This decision allows the biotech company to reallocate its resources towards the development of 4D-150, a gene therapy aimed at treating eye disease, which is now entering late-stage clinical studies. The shift underscores the company's commitment to advancing innovative treatments for eye diseases, leveraging its expertise in gene therapy to address unmet medical needs in this area.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

4DMT's 4D-150 Shows Promise in Wet AMD and DME, Advances to Phase 3 Trials

4DMT's 4D-150 demonstrates sustained delivery of anti-VEGF, reducing the need for frequent injections in wet AMD and DME patients.

4DMT Prioritizes 4D-150 and 4D-710, Extends Cash Runway into 2028

4DMT is focusing its pipeline on 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis, leveraging their strong clinical proof of concept.

Zhaoke Ophthalmology's TAB014 Shows Positive Phase 3 Results; Valo Health Shelves OPL-0401

Zhaoke Ophthalmology's TAB014 met primary and key secondary endpoints in a Phase 3 trial for wet age-related macular degeneration (AMD).

Merck Discontinues Development of Vibostolimab and Favezelimab Following Futility Analysis

Merck has halted the clinical development of vibostolimab, an anti-TIGIT antibody, after Phase 3 trials failed to meet overall survival futility criteria.

Genethon's GNT0004 Gene Therapy Shows Promise in Duchenne Muscular Dystrophy Trial

Genethon's GNT0004, a gene therapy for Duchenne muscular dystrophy (DMD), demonstrates positive initial results in a Phase 1/2/3 clinical trial, showing stable or improved motor function in treated patients.

Medigene AG Refocuses Strategy on TCR-Guided Therapies, Pauses MDG1015 Trial

Medigene AG is prioritizing R&D efforts towards generating 3S TCRs for off-the-shelf TCR-guided therapies, aiming for sensitive, specific, and safe cancer treatments.

Sarepta Discontinues Next-Gen DMD Drug Vesleteplirsen Amidst Regulatory Hurdles and Elevidys Success

Sarepta Therapeutics halts the development of vesleteplirsen, a next-generation exon 51-skipping therapy for Duchenne muscular dystrophy, after FDA feedback and internal analysis.

4DMT's 4D-150 Gene Therapy Shows Promise in Wet AMD, Phase 3 Trial Planned

4D Molecular Therapeutics' 4D-150 demonstrated an 89% reduction in the need for standard-of-care injections in wet AMD patients over 52 weeks.

Iovance's MDA-TIL Trial Terminated, Sention's ST-1891 Phase II Completed

Iovance Biotherapeutics' MDA-TIL Phase II trial was terminated due to lack of efficacy, significantly decreasing its Phase Transition Success Rate (PTSR) in ovarian, colorectal, and pancreatic cancers.

FDA Lifts Clinical Hold on 4D Molecular Therapeutics' Fabry Disease Gene Therapy Trial

The FDA has removed the clinical hold on the phase 1/2 INGLAXA trial for 4D Molecular Therapeutics' 4D-310, a gene therapy for Fabry disease, allowing patient enrollment to continue with plans for an update in 2025. The trial was previously halted due to serious adverse events, which have since resolved.

Reference News

[1]
4DMT tosses 2 programs, halts funds for 3 others as it ...
biotechjobs.io · Jan 10, 2025

4D Molecular Therapeutics is discontinuing two clinical programs and ceasing funding for three assets, reallocating reso...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy